Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

February 2024

Modulation of IL-23 Signalling with Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders with Active Psoriatic Arthritis

Arthritis Rheumatol 2024 doi 10.1002/art.42803 Epub ahead of print

Chen W,

Gao S,

Seridi L,

Chakravarty SD,

Shawi M,

Lavie F,

Xu XL,

Guselkumab treatment exhibited generally comparable and significant pharmacodynamic effects on IL-23/Th17–associated cytokines across participants with PsA who are biologic-naïve or have TNFi-IR. In coming to this conclusion, investigators assessed and compared immunologic differences and associations with clinical response to guselkumab in participants with active PsA who were biologic-naïve or TNFi-IR.

Keywords:

September 2023

Le guselkumab modifie les gènes différentiellement exprimés dans le sang des patients atteints de rhumatisme psoriasique : Résultats de deux essais de phase 3, randomisés et contrôlés par placebo

ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11589

Hsia EC,

Xu XL,

Song Q,

Gao S,

Chen W,

Miron M

Whole blood transcriptome profiling reveals differential gene expression in patients with active PsA from the DISCOVER-1 and DISCOVER-2 clinical studies in comparison with healthy controls.